Transferability of a European-derived Alzheimer’s Disease Genetic Risk Score across Multi-Ancestry Populations

Competing Interest Statement

C.C. has received research support from: GSK and EISAI. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid Genomics and Circular Genomics and owns stocks. L.M.P. received personal fees from Biogen for consulting activities unrelated to the submitted work T.G. received consulting fees from AbbVie, Alector, Anavex, Biogen, Cogthera, Eli Lilly, Functional Neuromodulation, Grifols, Iqvia, Janssen, Noselab, Novo Nordisk, NuiCare, Orphanzyme, Roche Diagnostics, Roche Pharma, UCB, and Vivoryon; lecture fees from Biogen, Eisai, Grifols, Medical Tribune, Novo Nordisk, Roche Pharma, Schwabe, and Synlab; and has received grants to his institution from Biogen, Eisai, and Roche Diagnostics.

Funding Statement

The work for this manuscript was further supported by the CoSTREAM project (www.costream.eu) and funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 667375. This work is also funded by la fondation pour la recherche medicale (FRM) (EQU202003010147) Italian Ministry of Health (Ricerca Corrente); Ministero dell'Istruzione, del l'Universita e della Ricerca MIUR project (Dipartimenti di Eccellenza 2018 2022) to Department of Neuroscience (Rita Levi Montalcini), University of Torino (IR), and AIRAlzh Onlus-ANCC-COOP (SB); Partly supported by (Ministero della Salute), I.R.C.C.S. Research Program, Ricerca Corrente 2018-2020, Linea n. 2 (Meccanismi genetici, predizione e terapie innovative delle malattie complesse) and by the (5 x 1000) voluntary contribution to the Fondazione I.R.C.C.S. Ospedale (Casa Sollievo della Sofferenza); and RF-2018-12366665, Fondi per la ricerca 2019 (Sandro Sorbi) and Italian Ministry of Health, Ricerca Corrente (RG, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli Brescia); Copenhagen General Population Study (CGPS): We thank staff and participants of the CGPS for their important contributions. Karolinska Institutet AD cohort: Dr. C.G. and co-authors of the Karolinska Institutet AD cohort report grants from Swedish Research Council (VR) 2015-02926, 2018-02754, 2015-06799, Swedish Alzheimer Foundation, Stockholm County Council ALF and resarch school, Karolinska Institutet StratNeuro, Swedish Demensfonden, and Swedish brain foundation, during the conduct of the study. ADGEN: This work was supported by Academy of Finland (grant numbers 307866); Sigrid Juselius Foundation; the Strategic Neuroscience Funding of the University of Eastern Finland; EADB project in the JPNDCO-FUND program (grant number 301220). CBAS: Supported by the Ministry of Health, Czech Republic―conceptual development of research organization, University Hospital Motol, Prague, Czech Republic Grant No. 00064203; Institutional Support of Excellence 2. LF UK Grant No. 699012; and The project National Institute for Neurological Research (Programme EXCELES, ID Project No. LX22NPO5107) - Funded by the European Union Next Generation EU. CNRMAJ-Rouen: This study received fundings from the Centre National de Reference Malades Alzheimer Jeunes (CNRMAJ). The Finnish Geriatric Intervention Study for the Prevention of Cognitive Impairment and Disability (FINGER) data collection was supported by grants from the Academy of Finland, La Carita Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Finnish Social Insurance Institution, Ministry of Education and Culture Research Grants, Yrj o Jahnsson Foundation, Finnish Cultural Foundation South Osthrobothnia Regional Fund, and EVO/State Research Funding grants of University Hospitals of Kuopio, Oulu and Turku, Seinajoki Central Hospital and Oulu City Hospital, Alzheimer Research & Prevention Foundation USA, AXA Research Fund, Knut and Alice Wallenberg Foundation Sweden, Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden, and Stiftelsen Stockholms sjukhem Sweden. FINGER cohort genotyping was funded by EADB project in the JPND CO-FUND (grant number 301220). Research at the Belgian EADB site is funded in part by the Alzheimer Research Foundation (SAO-FRA), The Research Foundation Flanders (FWO), and the University of Antwerp Research Fund. FK is supported by a fellowship of the University of Antwerp Research Fund. SNAC-K is financially supported by the Swedish Ministry of Health and Social Affairs, the participating County Councils and Municipalities, and the Swedish Research Council. BDR Bristol: We would like to thank the South West Dementia Brain Bank (SWDBB) for providing brain tissue for this study. The SWDBB is part of the Brains for Dementia Research programme, jointly funded by Alzheimer Research UK and Alzheimer Society and is supported by BRACE (Bristol Research into Alzheimer and Care of the Elderly) and the Medical Research Council. BDR Manchester: We would like to thank the Manchester Brain Bankfor providing brain tissue for this study. The Manchester Brain Bank is part of the Brains for Dementia Research programme, jointly funded by Alzheimer Research UK and Alzheimer Society. BDR KCL: Human post-mortem tissue was provided by the London Neurodegenerative Diseases Brain Bank which receives funding from the UK Medical Research Council and as part of the Brains for Dementia Research programme, jointly funded by Alzheimer Research UK and the Alzheimer Society. The CFAS Wales study was funded by the ESRC (RES-060-25-0060) and HEFCW as (Maintaining function and well-being in later life: a longitudinal cohort study). We are grateful to the NISCHR Clinical Research Centre for their assistance in tracing participants and in interviewing and in collecting blood samples, and to general practices in the study areas for their cooperation. MRC: We thank all individuals who participated in this study. Cardiff University was supported by the Alzheimer Society (AS; grant RF014/164) and the Medical Research Council (MRC; grants G0801418/1, MR/K013041/1, MR/L023784/1) (R.S. is an AS Research Fellow). Cardiff University was also supported by the European Joint Programme for Neurodegenerative Disease (JPND; grant MR/L501517/1), Alzheimer Research UK (ARUK; grant ARUK-PG2014-1), the Welsh Assembly Government (grant SGR544:CADR), Brain for dementia Research and a donation from the Moondance Charitable Foundation. Cardiff University acknowledges the support of the UK Dementia Research Institute, of which J.W. is an associate director. Cambridge University acknowledges support from the MRC. Patient recruitment for the MRC Prion Unit/UCL Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Biomedical Centre and NIHR Queen Square Dementia Biomedical Research Unit. The University of Southampton acknowledges support from the AS. King College London was supported by the NIHR Biomedical Research Centre for Mental Health and the Biomedical Research Unit for Dementia at the South London and Maudsley NHS Foundation Trust and by King College London and the MRC. ARUK and the Big Lottery Fund provided support to Nottingham University. A.Ram. : Part of the work was funded by the JPND EADB grant (German Federal Ministry of Education and Research (BMBF) grant: 01ED1619A). A. Ram. is also supported by the German Research Foundation (DFG) grants Nr: RA 1971/6-1, RA1971/7-1, and RA 1971/8-1. German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe): This study/publication is part of the German Research Network on Dementia (KND), the German Research Network on Degenerative Dementia (KNDD; German Study on Ageing, Cognition and Dementia in Primary Care Patients; AgeCoDe), and the Health Service Research Initiative (Study on Needs, health service use, costs and health-related quality of life in a large sample of oldestold primary care patients (85+ AgeQualiDe)) and was funded by the German Federal Ministry of Education and Research (grants KND: 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434; grants KNDD: 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716; grants Health Service Research Initiative: 01GY1322A, 01GY1322B, 01GY1322C, 01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G). VITA study: The support of the Ludwig Boltzmann Society and the AFI Germany have supported the VITA study. The former VITA study group should be acknowledged: W. Danielczyk, G. Gatterer, K Jellinger, S Jugwirth, KH Tragl, S Zehetmayer. Vogel Study: This work was financed by a research grant of the (Vogelstiftung Dr. Eckernkamp). HELIAD study: This study was supported by the grants: IIRG-09-133014 from the Alzheimer Association, 189 10276/8/9/2011 from the ESPA-EU program Excellence Grant (ARISTEIA) and the ΔΥ2β/οικ.51657/14.4.2009 of the Ministry for Health and Social Solidarity (Greece). Biobank Department of Psychiatry, UMG: Prof. Jens Wiltfang is supported by an Ilidio Pinho professorship and iBiMED (UID/BIM/04501/2013), and FCT project PTDC/DTP_PIC/5587/2014 at the University of Aveiro, Portugal. Lausanne study: This work was supported by grants from the Swiss National Research Foundation (SNF 320030_141179). PAGES study: Harald Hampel is an employee of Eisai Inc. During part of this work he was supported by the AXA Research Fund, the (Fondation partenariale Sorbonne Universite) and the (Fondation pour la Recherche sur Alzheimer), Paris, France. Mannheim, Germany Biobank: Department of geriatric Psychiatry, Central Institute for Mental Health, Mannheim, University of Heidelberg, Germany. Genotyping for the Swedish Twin Studies of Aging was supported by NIH/NIA grant R01 AG037985. Genotyping in TwinGene was supported by NIH/NIDDK U01 DK066134. WvdF is recipient of Joint Programming for Neurodegenerative Diseases (JPND) grants PERADES (ANR-13-JPRF-0001) and EADB (733051061). Gothenburg Birth Cohort (GBC) Studies: We would like to thank UCL Genomics for performing the genotyping analyses. The studies were supported by The Stena Foundation, The Swedish Research Council (2015-02830, 2013-8717), The Swedish Research Council for Health, Working Life and Wellfare (2013-1202, 2005-0762, 2008-1210, 2013-2300, 2013- 2496, 2013-0475), The Brain Foundation, Sahlgrenska University Hospital (ALF), The Alzheimer Association (IIRG-03-6168), The Alzheimer Association Zenith Award (ZEN-01-3151), Eivind och Elsa K:son Sylvans Stiftelse, The Swedish Alzheimer Foundation. Clinical AD, Sweden: We would like to thank UCL Genomics for performing the genotyping analyses. Barcelona Brain Biobank: Brain Donors of the Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS and their families for their generosity. Hospital Clinic de Barcelona Spanish Ministry of Economy and Competitiveness-Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, (Una manera de hacer Europa) grants (PI16/0235 to Dr. R. Sanchez-Valle and PI17/00670 to Dr. A.Antonelli). AA is funded by Departament de Salut de la Generalitat de Catalunya, PERIS 2016-2020 (SLT002/16/00329). Work at JP-T laboratory was possible thanks to funding from Ciberned and generous gifts from Consuelo Cervera Yuste and Juan Manuel Moreno Cervera. Sydney Memory and Ageing Study (Sydney MAS): We gratefully acknowledge and thank the following for their contributions to Sydney MAS: participants, their supporters and the Sydney MAS Research Team (current and former staff and students). Funding was awarded from the Australian National Health and Medical Research Council (NHMRC) Program Grants (350833, 568969, 109308). This work was supported by InnoMed (Innovative Medicines in Europe), an integrated project funded by the European Union of the Sixth Framework program priority (FP6-2004- LIFESCIHEALTH-5). Oviedo: This work was partly supported by Grant from Fondo de Investigaciones Sanitarias-Fondos FEDER EuropeanUnion to V.A. PI15/00878. Project MinE: The ProjectMinE study was supported by the ALS Foundation Netherlands and the MND association (UK) (Project MinE, www.projectmine.com). The SPIN cohort: We are indebted to patients and their families for their participation in the (Sant Pau Initiative on Neurodegeneration cohort), at the Sant Pau Hospital (Barcelona). This is a multimodal research cohort for biomarker discovery and validation that is partially funded by Generalitat de Catalunya (2017 SGR 547 to JC), as well as from the Institute of Health Carlos III-Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER- (Una manera de Hacer Europa)) (grants PI11/02526, PI14/01126, and PI17/01019 to JF; PI17/01895 to AL), and the Centro de Investigacion Biomedica en Red Enfermedades Neurodegenerativas programme (Program 1, Alzheimer Disease to AL). We would also like to thank the Fundacio Bancaria Obra Social La Caixa (DABNI project) to JF and AL; and Fundacion BBVA (to AL), for their support in funding this follow-up study. Adolfo Lopez de Munain is supported by Fundacion Salud 2000 (PI2013156), CIBERNED and Diputacion Foral de Gipuzkoa (Exp.114/17). P.S.J. is supported by CIBERNED and Carlos III Institute of Health, Spain (PI08/0139, PI12/02288, and PI16/01652, PI20/01011), jointly funded by Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, (Una manera de hacer Europa). We thank Biobanco Valdecilla for their support. Dr. Fermin Moreno is supported by the Tau Consortium and has received funding from the Carlos III Health Institute (PI19/01637). Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The AlzheimerCenter Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer&Dementia biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number #733051061). This research is performed by using data from the Parelsnoer Institute an initiative of the Dutch Federation of University Medical Centres (www.parelsnoer.org). 100-Plus study: We are grateful for the collaborative efforts of all participating centenarians and their family members and/or relations. We thank the Netherlands Brain Bank for supplying DNA for genotyping. This work was supported by Stichting AlzheimerNederland (WE09.2014-03), Stichting Diorapthe, Horstingstuit foundation, Memorabel (ZonMW project number #733050814, #733050512) and Stichting VUmcFonds. Additional support for EADB cohorts: WF, SL, HH are recipients of ABOARD, a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). The DELCODE study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE)), reference number BN012. Gra@ce. We would like to thank patients and controls who participated in this project. The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundacion bancaria (La Caixa), Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). AR and MB receive support from the European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). MB and AR are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301 and PI22/01403. Accion Estrategica en Salud is integrated into the Spanish National R+D+I Plan and funded by ISCIII Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER (Una manera de hacer Europa)). AR is also funded by JPco-fuND-2 (Multinational research projects on Personalized Medicine for Neurodegenerative Diseases), PREADAPT project (ISCIII grant: AC19/00097), EURONANOMED III Joint Transnational call for proposals (2017) for European Innovative Research & Technological Development Projects in Nanomedicine (ISCIII grant: AC17/00100), the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU), The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant N AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant N PR067/21, Janssen. And DESCARTES project funded by German Research Foundation (DFG). I.dR. is supported by a national grant from the Instituto de Salud Carlos III FI20/00215. Ace Alzheimer Center Barcelona research receives support from Roche, Janssen, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de Analisis Echevarne, and IrsiCaixa. Some control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain); they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. EADI. This work has been developed and supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer disease) including funding from MEL (Metropole europenne de Lille), ERDF (European Regional Development Fund) and Conseil Regional Nord Pas de Calais. This work was supported by INSERM, the National Foundation for Alzheimer disease and related disorders, the Institut Pasteur de Lille and the Centre National de Recherche en Genomique Humaine, CEA, the JPND PERADES, the Laboratory of Excellence GENMED (Medical Genomics) grant no. ANR-10-LABX-0013 managed by the National Research Agency (ANR) part of the Investment for the Future program, and the FP7 AgedBrainSysBio. The Three-City Study was performed as part of collaboration between the Institut National de la Sante et de la Recherche Medicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthelabo. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, MGEN, Institut de la Longevite, Agence Francaise de Securite Sanitaire des Produits de Sante, the Aquitaine and Bourgogne Regional Councils, Agence Nationale de la Recherche, ANR supported the COGINUT and COVADIS projects. Fondation de France and the joint French Ministry of Research/INSERM (Cohortes et collections de donnes biologiques) programme. Lille Genopole received an unconditional grant from Eisai. The Three-city biological bank was developed and maintained by the laboratory for genomic analysis LAG-BRC - Institut Pasteur de Lille. GERAD/PERADES. We thank all individuals who participated in this study. Cardiff University was supported by the Wellcome Trust, Alzheimer Society (AS; grant RF014/164), the Medical Research Council (MRC; grants G0801418/1, MR/K013041/1, MR/L023784/1), the European Joint Programme for Neurodegenerative Disease (JPND, grant MR/L501517/1), Alzheimer Research UK (ARUK, grant ARUK-PG2014-1), Welsh Assembly Government (grant SGR544:CADR), a donation from the Moondance Charitable Foundation, UK Dementia Platform (DPUK, reference MR/L023784/1), and the UK Dementia Research Institute at Cardiff. Cambridge University acknowledges support from the MRC. ARUK supported sample collections at the Kings College London, the South West Dementia Bank, Universities of Cambridge, Nottingham, Manchester and Belfast. King College London was supported by the NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at the South London and Maudsley NHS Foundation Trust and Kings College London and the MRC. Alzheimer Research UK (ARUK) and the Big Lottery Fund provided support to Nottingham University. Ulster Garden Villages, AS, ARUK, American Federation for Aging Research, NI R&D Office and the Royal College of Physicians/Dunhill Medical Trust provided support for Queen University, Belfast. The University of Southampton acknowledges support from the AS. The MRC and Mercer Institute for Research on Ageing supported the Trinity College group. DCR is a Wellcome Trust Principal Research fellow. The South West Dementia Brain Bank acknowledges support from Bristol Research into Alzheimer and Care of the Elderly. The Charles Wolfson Charitable Trust supported the OPTIMA group. Washington University was funded by NIH grants, Barnes Jewish Foundation and the Charles and Joanne Knight Alzheimer Research Initiative. Patient recruitment for the MRC Prion Unit/UCL Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Biomedical Research Centre and their work was supported by the NIHR Queen Square Dementia BRU, the Alzheimer Research UK and the Alzheimer Society. LASER-AD was funded by Lundbeck SA. The AgeCoDe study group was supported by the German Federal Ministry for Education and Research grants 01 GI 0710, 01 GI 0712, 01 GI 0713, 01 GI 0714, 01 GI 0715, 01 GI 0716, 01 GI 0717. Genotyping of the Bonn case-control sample was funded by the German centre for Neurodegenerative Diseases (DZNE), Germany. The GERAD Consortium also used samples ascertained by the NIMH AD Genetics Initiative. HH was supported by a grant of the Katharina-Hardt-Foundation, Bad Homburg vor der H ohe, Germany. The KORA F4 studies were financed by Helmholtz Zentrum Munchen; German Research Center for Environmental Health; BMBF; German National Genome Research Network and the Munich Center of Health Sciences. The Heinz Nixdorf Recall cohort was funded by the Heinz Nixdorf Foundation and BMBF. We acknowledge use of genotype data from the 1958 Birth Cohort collection and National Blood Service, funded by the MRC and the Wellcome Trust which was genotyped by the Wellcome Trust Case Control Consortium and the Type-1 Diabetes Genetics Consortium, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, National Institute of Child Health and Human Development and Juvenile Diabetes Research Foundation International. The project is also supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (United Kingdom, Medical Research Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)) and through the Motor Neurone Disease Association. This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King College London. Prof Jens Wiltfang is supported by an Ilidio Pinho professorship and iBiMED (UID/BIM/04501/2013), at the University of Aveiro, Portugal. DemGene. The project has received funding from The Research Council of Norway (RCN) Grant Nos. 213837, 223273, 225989, 248778, and 251134 and EU JPND Program RCN Grant Nos. 237250, 311993, the South-East Norway Health Authority Grant No. 2013-123, the Norwegian Health Association, and KG Jebsen Foundation. The RCN FRIPRO Mobility grant scheme (FRICON) is co-funded by the European Union Seventh Framework Programme for research, technological development and demonstration under Marie Curie grant agreement No 608695. European Community grant PIAPP-GA-2011-286213 PsychDPC.. Bonn study. This group would like to thank Dr. Heike Koelsch for her scientific support. The Bonn group was funded by the German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant number 01GI0102, 01GI0711, 01GI042 China. This Chinese AD WGS cohort was supported in part by the National Key R&D Program of China (2021YFE0203000); the Areas of Excellence Scheme of the University Grants Committee (AoE/M-604/16); the Research Grants Council of Hong Kong (the Collaborative Research Fund [C6027-19GF] and the Theme-Based Research Scheme [T13-605/18W]); the Innovation and Technology Commission (InnoHK Funding Scheme; ITCPD/17-9, ITS/207/18FP, MRP/042/18X and MRP/097/20X); Chow Tai Fook Charity Foundation; the Guangdong Provincial Key S&T Program Grant (2018B030336001); the Guangdong Provincial Fund for Basic and Applied Basic Research (2019B1515130004); and the Fundamental Research Program of Shenzhen Virtual University Park (2021Szvup137). Japan. This study is supported by AMED JP23dk0207060 and JP23wm0525019. Korea. This research was supported by a National Research Foundation of Korea grant, funded by the Korean government (MSIT) (No. 2022R1A2C2009998); the ICT Creative Consilience program (No. IITP-2022-2020-0-01821) supervised by the Institute for Information & Communications Technology Planning & Evaluation (IITP); the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (Nos. HU22C0042, HU21C0111, and HI19C1132); the Ministry of Science and ICT, Republic of Korea (No. 2019RIA5A2026045); the National Institute of Health research project (No. 2021-ER1006-01); and Future Medicine 20*30 Project of the Samsung Medical Center (No. SMX1220021). This study was provided with biospecimens and data from the biobank of Chronic Cerebrovascular Disease consortium. The consortium was supported and funded by the Korea Centers for Disease Control and Prevention (No. 4845-303). Sub Saharan Africa (EPIDEMCA). Sub Saharan Africa (EPIDEMCA). This study was supported by a grant from the French National Research Agency (ANR-09-MNPS-009-01),the AXA research Fund (2012 Project Public Health Institute (Inserm) PREUX Pierre-Marie) and the Limoges University Hospital through its APREL scheme. The sponsors of the study had no role in study design, data collection, data interpretation or writing of the report. We also thank the staffs of the Universities of Bangui (Central African Republic) and Marien Ngouabi in Brazzaville (ROC); Pasteur Institute in Bangui and (Laboratoire National de Sante Publique) in Brazzaville; Health ministries of the Central African Republic and the Republic of Congo, for their moral support; University of Limoges, Doctoral School of Limoges University, Inserm; Limousin Regional Council. We are very grateful to all the participants to this survey, the investigators, and staffs of Bangui and Brazzaville hospitals for their assistance Argentina. This study was supported by funding from Alexander von Humboldt Foundation and International Society for Neurochemistry (ISN) to M.C.D.; the Agencia Nacional de Promocion Cientifica y Tecnologica (PID-2011-0059, PIBT/09-2013, PICT-2016-4647 and PICT2019-0656 to L.M.) and from EU-LAC Health-Neurodegeneration JOINT CALL 2016 (EULACH16 to L.M.). Chile. The Funding of the ALEXANDROS study was provided by the Chilean National Fund for Science and Technology (FONDECYT) grant 1130947. The genotyping for the Chilean and Tunisian series were funded by Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE), supported by Grifols SA, Fundacion bancaria (La Caixa), Ace Alzheimer Center Barcelona and CIBERNED. Brazil. The study was supported by the Brazilian National Council for Scientific and Technological Development (CNPq): processes 315133/2021-0, 309953/2018-9, 436735/2018-0) FAPEMIG:processes:APQ-02662-14, APQ-02662-14) and the Coordination for the Improvement of Higher Education Personnel (CAPES): process 88887.569376/2020-00. Colombia. This was supported by Ministerio de Ciencia, Tecnologia e Innovacion (MINCIENCIAS) and the Universidad Nacional de Colombia. We also thanks all the participants who kindly agreed to participate in the study. ADSP. The ADGC cohorts include Adult Changes in Thought (ACT) (U01 AG006781, U19 AG066567),the Alzheimer Disease Research Centers (ADRC) (P30AG062429, P30 AG066468, P30AG062421, P30AG066509, P30AG066514, P30AG066530, P30AG066507, P30AG066444, P30AG066518, P30AG066512, P30AG066462, P30AG072979, P30AG072972, P30AG072976, P30AG072975, P30AG072978, P30AG072977, P30AG066519, P30AG062677, P30AG079280, P30AG062422, P30AG066511, P30AG072946, P30AG062715, P30AG072973, P30AG066506, P30AG066508, P30AG066515, P30AG072947, P30AG072931, P30AG066546, P20AG068024, P20AG068053, P20AG068077, P20AG068082, P30AG072958, P30AG072959), the Chicago Health and Aging Project (CHAP) (R01 AG11101, RC4 AG039085, K23 AG030944), Indiana Memory and Aging Study (IMAS) (R01 AG019771), Indianapolis Ibadan (R01 AG009956, P30 AG010133), the Memory and Aging Project (MAP) (R01 AG17917), Mayo Clinic (MAYO) (R01 AG032990, U01AG046139, R01 NS080820, RF1 AG051504, P50 AG016574), Mayo Parkinson Disease controls (NS039764, NS071674, 5RC2HG005605), University of Miami (R01 AG027944, R01 AG028786, R01 AG019085, IIRG09133827, A2011048), the Multi-Institutional Research in Alzheimer Genetic Epidemiology Study (MIRAGE) (R01 AG09029, R01 AG025259), the National Centralized Repository for Alzheimer Disease and Related Dementias (NCRAD) (U24 AG021886), the National Institute on Aging Late Onset Alzheimer Disease Family Study (NIA- LOAD) (U24AG056270), the Religious Orders Study (ROS) (P30 AG10161, R01 AG15819), the Texas Alzheimer Research and Care Consortium (TARCC) (funded by the Darrell K Royal Texas Alzheimer Initiative), Vanderbilt University/Case Western Reserve University (VAN/CWRU) (R01AG019757, R01 AG021547, R01 AG027944, R01 AG028786, P01 NS026630, and Alzheimer Association), the Washington Heights-Inwood Columbia Aging Project (WHICAP) (RF1AG054023), the University of Washington Families (VA Research Merit Grant, NIA: P50AG005136, R01AG041797, NINDS: R01NS069719), the Columbia University Hispanic Estudio Familiar de Influencia Genetica de Alzheimer (EFIGA) (RF1 AG015473), the University of Toronto (UT)(funded by Wellcome Trust, Medical Research Council, Canadian Institutes of Health Research), and Genetic Differences (GD) (R01 AG007584). The CHARGE cohorts are supported in part by National Heart, Lung, and Blood Institute (NHLBI) infrastructure grant HL105756 (Psaty), RC2HL102419 (Boerwinkle) and the neurology working group is supported by the National Institute on Aging (NIA) R01 grant AG033193. The CHARGE cohorts The CHARGE cohorts participating in the ADSP include the following: Austrian Stroke Prevention Study (ASPS), ASPS-Family study, and the Prospective Dementia Registry-Austria (ASPS/PRODEM-Aus), the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Erasmus Rucphen Family Study (ERF), the Framingham Heart Study (FHS), and the Rotterdam Study (RS). ASPS is funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180 and the Medical University of Graz. The ASPS-Fam is funded by the Austrian Science Fund (FWF) project I904), the EU Joint Programme Neurodegenerative Disease Research (JPND) in frame of the BRIDGET project (Austria, Ministry of Science) and theMedical University of Graz and the Steiermarkische Krankenanstalten Gesellschaft. PRODEM-Austria is supported by the Austrian Research Promotion agency (FFG) (Project No.827462) and by the Austrian National Bank (Anniversary Fund, project 15435. ARIC research is .CC-BY-NC-ND 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The collaborative study is also supported by NHLBI contracts (HHSN268201100005C,HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,Neurocognitive data in ARIC is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902,2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD), and with previous brain MRI examinations funded by R01-HL70825 from the NHLBI. CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295 and U01HL130114 from the NHLBI with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629, R01AG15928, and R01AG20098 from the NIA. FHS research is supported by NHLBI contracts N01-HC-25195 and HHSN268201500001I. This study was also supported by additional grants from the NIA (R01s AG054076, AG049607 and AG033040 and NINDS (R01 NS017950). The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4- 2007-201413 by the European Commission under the programme (Quality of Life and Management of the Living Resources) of 5th Framework Programme (no.QLG2-CT-2002- 01254). High-throughput analysis of the ERF data was supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). The Rotterdam Study is funded by Erasmus Medical Center. Genetic data sets are also supported by the Netherlands Organization of Scientific Research NWO Investments (175.010.2005.011,584 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project 050-060-810. All studies are grateful to their participants, faculty and staff. The content of these manuscripts is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the U.S. Department of Health and Human Services. In addition, funding to support and share the ADSP data are included here: NIA U54-AG052427 and NIA U24-AG041689. The Sacramento Area Latino Study on Aging (SALSA). This study was funded by the National Institutes of Health, including the National Institute on Aging under Award Numbers K01AG056602 and R01AG12975 and the National Institute for Diabetes and Digestive and Kidney Diseases under Award Numbers R01 DK60753 and R01DK087864. MVP. This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by VA BLR&D grants 1 I01 BX004192 (MVP015) and I01BX005749 (MVP040). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Written informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian or other proxy. Study protocols for all cohorts were reviewed and approved by the appropriate institutional review boards. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes